{"id":602985,"date":"2022-06-06T18:26:01","date_gmt":"2022-06-06T18:26:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=602985"},"modified":"2022-06-06T18:26:01","modified_gmt":"2022-06-06T18:26:01","slug":"xerostomia-market-to-showcase-robust-growth-in-the-upcoming-years-asserts-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/xerostomia-market-to-showcase-robust-growth-in-the-upcoming-years-asserts-delveinsight_602985.html","title":{"rendered":"Xerostomia Market to Showcase Robust Growth in the Upcoming Years, asserts DelveInsight"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1654356598.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Xerostomia Market to Showcase Robust Growth in the Upcoming Years, asserts DelveInsight\" src=\"https:\/\/www.abnewswire.com\/uploads\/1654356598.jpeg\" alt=\"Xerostomia Market to Showcase Robust Growth in the Upcoming Years, asserts DelveInsight\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>Xerostomia Market<\/div>\n<\/div>\n<\/div>\n<p style=\"text-align: justify;\"><strong>Xerostomia<\/strong>&nbsp;is defined as the &ldquo;complaint of oral dryness&rdquo;. It can occur due to inadequate salivary secretion secondary to abnormal function of the salivary glands, which is categorized as &ldquo;true&rdquo; xerostomia; however, most patients with xerostomia often do not have objective signs of hypo salivation. &ldquo;Symptomatic&rdquo; xerostomia or &ldquo;pseudo&rdquo; xerostomia refers to oral dryness despite normal salivary gland function.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">DelveInsight&#8217;s &#8220;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/xerostomia-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\"><strong>Xerostomia Market<\/strong><\/a><strong> Insights, Epidemiology, and Market Forecast-2032&#8243;<\/strong>&nbsp;report delivers an in-depth understanding of the Xerostomia, historical and forecasted epidemiology as well as the Xerostomia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n<p style=\"text-align: justify;\">The causes of xerostomia may be divided into two broad categories: systemic diseases and local factors. Systemic diseases that can cause xerostomia include, but are not limited to, endocrine, autoimmune, infectious, and granulomatous diseases. The more common systemic diseases are reviewed here. Local factors that can cause xerostomia include medications, head and neck radiation therapy, and lifestyle factors.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Get Free Sample Copy of Report at: <\/strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/xerostomia-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\"><strong>https:\/\/www.delveinsight.com\/sample-request\/xerostomia-market<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Some facts of the Xerostomia Market&nbsp;are:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>As per a study titled &ldquo;Dry mouth treatment&rdquo; (2018), Dry mouth (or xerostomia), a condition affectingmore than 80 million people in the high-income countries, is a chronic and mostly irreversible conditioninduced, mainly, as a side effect of hundreds of commonly used medications, by radiation therapy forhead &amp; neck cancer, and by auto-immune diseases.<\/li>\n<li>The above mentioned study also estimated the global market for dry mouth to be about USD 2 Billion.<\/li>\n<li>The prevalence of xerostomia, of low stimulated salivary flow rate and low at rest salivary flow rate were 338 (38.8%), 494 (56.6%), 320 (36.7%), respectively in South Brazil. And important portion of the sample con \u2010 currently presented xerostomia and salivary hypofunction (22.4%; n = 173). The sample included the average age of 68.5 &plusmn; 6.7 years, and the majority of the sample was comprised of women (65.3%).<\/li>\n<li>The prevalence of hyposalivation and xerostomia in older persons. Its findings revealed a prevalence of 59.7% of hypos\u2010alivation and 25.2% of xerostomia, with 16.5% presenting both.<\/li>\n<li>Xerostomia is more common in females than in males<\/li>\n<li>Orellana et al. observed the prevalence of xerostomia ranged from 0.9% to 64.8%. The majority of data collected for these studies was in Scandinavia (most patients age greater than 50, the rest being over 18). [2006].<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Some of <\/strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/xerostomia-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\"><strong>Xerostomia Companies<\/strong><\/a><strong> involved:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Lubris BioPharma<\/li>\n<li>MeiraGTx UK II Ltd<\/li>\n<li>GlaxoSmithKline PLC<\/li>\n<li>Parnell Pharmaceuticals Inc.<\/li>\n<li>Bausch Health Companies Inc.<\/li>\n<li>Synedgen Inc. (Prisyna)<\/li>\n<li>3M company<\/li>\n<li>And Many Others<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Get Free Sample Copy of Report at: <\/strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/xerostomia-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\"><strong>https:\/\/www.delveinsight.com\/sample-request\/xerostomia-market<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/xerostomia-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\"><strong>Xerostomia therapies<\/strong><\/a><strong> Covered:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>LBS020<\/li>\n<li>AAV-AQP1<\/li>\n<li>And Many Others<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Get Free Sample Copy of Report at: https:\/\/www.delveinsight.com\/sample-request\/xerostomia-market<\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Table of Contents:<\/strong><\/p>\n<p style=\"text-align: justify;\">1. Key Insights<\/p>\n<p style=\"text-align: justify;\">2. Executive Summary of Xerostomia<\/p>\n<p style=\"text-align: justify;\">3. Competitive Intelligence Analysis for Xerostomia<\/p>\n<p style=\"text-align: justify;\">4. Xerostomia: Market Overview at a Glance<\/p>\n<p style=\"text-align: justify;\">5. Xerostomia: Disease Background and Overview<\/p>\n<p style=\"text-align: justify;\">6. Patient Journey<\/p>\n<p style=\"text-align: justify;\">7. Xerostomia Epidemiology and Patient Population<\/p>\n<p style=\"text-align: justify;\">8. Treatment Algorithm, Current Treatment, and Medical Practices<\/p>\n<p style=\"text-align: justify;\">9. Unmet Needs<\/p>\n<p style=\"text-align: justify;\">10. Key Endpoints of Xerostomia Treatment<\/p>\n<p style=\"text-align: justify;\">11. Marketed Products<\/p>\n<p style=\"text-align: justify;\">12. Emerging Therapies<\/p>\n<p style=\"text-align: justify;\">13. Xerostomia: Seven Major Market Analysis<\/p>\n<p style=\"text-align: justify;\">14. Attribute analysis<\/p>\n<p style=\"text-align: justify;\">15. 7MM: Market Outlook<\/p>\n<p style=\"text-align: justify;\">16. Access and Reimbursement Overview of Xerostomia<\/p>\n<p style=\"text-align: justify;\">17. KOL Views<\/p>\n<p style=\"text-align: justify;\">18. Market Drivers<\/p>\n<p style=\"text-align: justify;\">19. Market Barriers<\/p>\n<p style=\"text-align: justify;\">20. Appendix<\/p>\n<p style=\"text-align: justify;\">21. DelveInsight Capabilities<\/p>\n<p style=\"text-align: justify;\">22. Disclaimer<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>About&nbsp;DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.&nbsp;<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56434.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Ankit Nigam<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=xerostomia-market-to-showcase-robust-growth-in-the-upcoming-years-asserts-delveinsight\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +19193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Albany<br \/><strong>State:<\/strong> New York<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/report-store\/xerostomia-market\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/report-store\/xerostomia-market<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/report-store\/xerostomia-market\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=xerostomia-market-to-showcase-robust-growth-in-the-upcoming-years-asserts-delveinsight\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Xerostomia Market Xerostomia&nbsp;is defined as the &ldquo;complaint of oral dryness&rdquo;. It can occur due to inadequate salivary secretion secondary to abnormal function of the salivary glands, which is categorized as &ldquo;true&rdquo; xerostomia; however, most patients with xerostomia often do not &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/xerostomia-market-to-showcase-robust-growth-in-the-upcoming-years-asserts-delveinsight_602985.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,406,404,416],"tags":[],"class_list":["post-602985","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-US","category-World"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/602985","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=602985"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/602985\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=602985"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=602985"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=602985"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}